Recombinant antibodies: From the laboratory to the clinic

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 4, 2006, Pages 285-304

  Albrecht, Huguette ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody targeted therapy; Immunoconjugates; Immunoparticles; Pretargeting; Recombinant antibody fragments; Therapeutic index

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CDP 791; CETUXIMAB; DENOSUMAB; GEMTUZUMAB OZOGAMICIN; HGS ETR1; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN LMB2; MATUZUMAB; MLN 2704; PANITUMUMAB; PERTUZUMAB; RECOMBINANT ANTIBODY; RFT 5DGA; RITUXIMAB; SGN 40; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB PLUS PERTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; BREAST CANCER; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG RECEPTOR BINDING; HEAD AND NECK CANCER; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 33750612078     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.285     Document Type: Review

References (139)

1. Kohler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975;256:495.
2. Reilly RM, J Sandhu, TM Alvarez-Diez, et al. Problems of delivery, of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126.
3. Pavlou AK, and Reichert JM. Recombinant protein therapeutics-success rates, market trends, and values to 2010. Nat Biotech 2004;22:1513.
4. Padlan EA. Anatomy of the antibody molecule. Mol Immunol 1994;31:169.
5. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81:6851.
6. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984;312:643.
7. Qu Z, Griffiths GL, Wegener WA, et al. Development of humanized antibodies as cancer therapeutics. Methods 2005;36:84.
8. Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988;240:1038.
9. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: Recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85:5879.
10. Glockshuber R, Malia M, Pfitzinger I, et al. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 1990;29:1362.
11. Orlandi R, Gussow DH, Jones PT, et al. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:3833.
12. Ward ES, Gussow D, Griffiths AD, et al. Binding activities of a repertoire of single immunglobulin variable domains secreted from Escherichia coli, Nature 1989;341:544.
13. Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001; 989.
14. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotech 2005;23:1126.
15. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446.
16. Greenberg AS, Avila D, Hughes M, et al. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995;374:168.
17. Nuttall SD, Krishnan UV, Hattarki M, et al. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol Immunol 2001;38:313.
18. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004;64:2853.
19. Pluckthun A, Pack P. New protein engineering approches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83.
20. Kriangkum J, Xu B, Nagata LP, et al. Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 2001;18:31.
21. Carter P. Bispecific human IgG by design. J Immunol Meth 2001;248:7.
22. Todorovska A, Roovers RC, Dolezal O, et al. Design and application of diabodies, triabodies, and tetrabodies for cancer targeting. J Immunol Meth 2001;248:47.
23. Holliger P, Prospero T, Winter G. "Diabodies": Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993;90:6444.
24. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 2006;103:6841.
25. Kellermann SA, Green LL. Antibody discovery: The use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotech 2002;13:593.
26. Marks JD, Hoogenboom HR, Bonnert TP, et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;222:581.
27. Knappik A, Ge L, Honegger A, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000;296:57.
28. McCafferty J, Griffiths AD, Winter G, et al. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990;348:552.
29. Douthwaite J, Jermutus L. Exploiting directed evolution for the discovery of biologicals. Curr Opin Drug Discov Devel 2006;9:269.
30. Lipovsek D, Pluckthun A. In vitro protein evolution by ribosome display and mRNA display. J Immunol Meth 2004;290:51.
31. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotech 1997;15:553.
32. Mossner E, Koch H, Pluckthun A. Fast selection of antibodies without antigen purification: Adaptation of the protein fragment complementation assay to select antigen-antibody pairs. J Mol Biol 2001;308:115.
33. Andersen DC, Reilly DE. Production technologies for monoclonal antibodies and their fragments. Curr Opin Biotech 2004;15:456.
34. Sinacola JR, Robinson AS. Rapid refolding and polishing of single-chain antibodies from Escherichia coli inclusion bodies. Prot Expr Purif 2002;26:301.
35. Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science 2001;291:2364.
36. Andersen DC, Krummen L. Recombinant protein expression for therapeutic applications. Curr Opin Biotech 2002;13:117.
37. Hunter CV, Tiley LS, Sang HM. Developments in transgenic technology: Applications for medicine. Trends Mol Med 2005;1:293.
38. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: Production of antibodies, biopharmaceuticals, and edible vaccines in plants. Trends Plant Sci 2001;6:219.
39. Raju TS, Briggs JB, Borge SM, et al. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000;10:477.
40. Ivarie R. Competitive bioreactor hens on the horizon. Trends Biotech 2006;24:99.
41. Hamilton SR, Bobrowicz P, Bobrowicz B, et al. Production of complex human glycoproteins in yeast. Science 2003;301:1244.
42. Humphreys DP, Glover DJ. Therapeutic antibody production technologies: Molecules, applications, expression, and purification. Curr Opin Drug Discov Devel 2001;4:172.
43. Mayer A, Tsiompanou E, O'Malley D, et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA, single-chain Fv antibody. Clin Cancer Res 2000;6:1711.
44. Goel A, Beresford GW, Colcher D, et al. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: Expression, purification, and characterization. J Biochem (Tokyo) 2000;127:829.
45. Mayer A, Sharma SK, Tolner B, et al. Modifying an immunogenic epitope on a therapeutic protein: A step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer 2004;90:2402.
46. Nellis DF, Ekstrom DL, Kirpotin DB, et al. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotech Prog 2005;21:205.
47. Knauf MJ, Bell DP, Hirtzer P, et al. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 1988;263:15064.
48. Yang K, Basu A, Wang M, et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Prot Eng 2003;16:761.
49. Kubetzko S, Sarkar CA, Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 2005;68:1439.
50. Ober RJ, Radu CG, Ghetie V, et al. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int Immunol 2001;13:1551.
51. Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005;65:622.
52. East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta 2002;1572:364.
53. Medzihradszky KF, Spencer DI, Sharma SK, et al. Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 2004;14:27.
54. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406.
55. Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006;12:1599.
56. Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998;77:1405.
57. Adams GP, Schier R, McCall AM, et al. High-affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 2001;61:4750.
58. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Res 1990;50:4478.
59. Jain M, Chauhan SC, Singh AP, et al, Penetratin improves tumor retention of single-chain antibodies: A novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res 2005;65:7840.
60. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488.
61. Chmura AJ, Orton MS, Meares CF. Antibodies with infinite affinity. Proc Natl Acad Sci USA 2001;98:8480.
62. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825.
63. Kukis DL, Novak-Hofer I, DeNardo SJ. Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer. Cancer Biother Radiopharm 2001;16:457.
64. Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotech Adv 2001;19:435.
65. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1:553.
66. Kreitman RJ. Toxin-labeled monoclonal antibodies. Curr Pharm Biotech 2001;2:313.
67. Brinkmann U, Mansfield E, Pastan I. Effects of BCL-2 overexpression on the sensitivity of MCF-7 breast cancer cells to ricin, diphtheria, and Pseudomonas toxin and immunotoxins. Apoptosis 1997;2:192.
68. Tsutsumi Y, Onda M, Nagata S, et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-TAC(FV)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenecity. Proc Natl Acad Sci USA 2000;97:8548.
69. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002;20:274.
70. Newton DL, Hansen HJ, Mikulski SM, et al. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin's lymphoma. Blood 2001;97:528.
71. Bagshawe KD, Springer CJ, Searle F, et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988;58:700.
72. Sharma SK, Bagshawe KD, Begent RH. Advances in antibody-directed enzyme prodrug therapy. Curr Opin Invest Drugs 2005;6:611.
73. Roberge M, Estabrook M, Basler J, et al. Construction and optimization of a CC49-based scFv-beta-lactamase fusion protein for ADEPT. Prot Eng Des Sel 2006;19:141.
74. van Vlerken LE, Amiji MM. Multifunctional polymeric nanoparticles for tumour-targeted drug delivery. Exp Opin Drug Deliv 2006;3:205.
75. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Cont Rel 2000;65:271.
76. Albrecht H, Burke PA, Natarajan A, et al. Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand. Bioconj Chem 2004;15:16.
77. Nielsen TJB, Geierstanger BH. Multiplexed sandwich assays in microarray format. J Immunol Meth 2004;290:107.
78. Taube SE, Jacobson JW, Lively TG. Cancer diagnostics: Decision criteria for marker utilization in the clinic. Am J Pharmacogenom 2005;5:357.
79. Hricak H, Schoder H, Pucar D, et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 2003;30:616.
80. 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med 2000;41:1657.
81. Pohlman B, Sweetenham J, Macklis RM. Review of clinical radioimmunotherapy. Exp Rev Anticancer Ther 2006;6:445.
82. Wu AM, Chen W, Raubitschek A, et al. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by noncovalent dimers. Immunotech 1996;2:21.
83. Delgado C, Francis GE, Fischer D. Uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249.
84. Beresford GW, Pavlinkova G, Booth BJM, et al. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int J Cancer 1999;81:911.
85. Wu AM, Yasaki PJ, Tsai SW, et al. High-resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA 2000;97:8495.
86. 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004;10:5014.
87. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;1:1250.
88. Roffler SR, Wang HE, Yu HM, et al. A membrane antibody receptor for noninvasive imaging of gene expression. Gene Ther 2006;13:412.
89. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005;11:7967.
90. Ramjiawan B, Maiti P, Aftanas A, et al. Noninvasive localization of tumors by immunofluorescence imaging using a single-chain Fv fragment of a human monoclonal antibody with broad cancer specificity. Cancer 2000;89:1134.
91. Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotech 2004;22:969.
92. Huh YM, Jun YW, Song HT, et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 2005;127:12387.
93. Ragupathi G, Gathuru J, Livingston P. Antibody inducing polyvalent cancer vaccines. Cancer Treat Res 2005;123:157.
94. Kipriyanov SM, Le GF. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Devel 2004;7:233.
95. Katsumata M, Okudaira T, Samanta A, et al. Prevention of breast tumour development in vivo by down-regulation of the p185neu receptor. Nat Med 1995;1:644.
96. Lollini PL, Nicoletti G, Landuzzi L, et al. New target antigens for cancer immunoprevention. Curr Cancer Drug Targ 2005;5:221.
97. Johnson P, Glennie P. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003;30:3.
98. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825.
99. DeNardo GL. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 2005;35:202.
100. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441.
101. Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell 2003;3:207.
102. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768.
103. Carter P, Fendly BM, Lewis GD, et al. Development of herceptin. Breast Dis 2000;11:103.
104. Mina L, Sledge GW, Jr. Twenty years of systemic therapy for breast cancer. Oncology (Williston Park) 2006;20:25.
105. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659.
106. Walshe JM, Denduluri N, Berman AW, et al. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer 2006;6:535.
107. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55:717.
108. Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol 2005;32:S43.
109. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335.
110. Amgen and Abgenix Inc. Panitumumab improves progression-free survival in metastatic colorectal cancer. Oncology 2005;19:1800.
111. 131I-labetuzumab after salvage resection of colorectal matastases in the liver: Five-year safety and efficacy results. J Clin Oncol 2005;23:6763.
112. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2004;22:2610.
113. Kindler HL. In focus: Advanced pancreatic cancer. Clin Adv Hematol Oncol 2005;3:420.
114. Mamelak AN. Locoregional therapies for glioma. Oncology (Williston Park) 2005;19:1803.
115. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 2005;56:1243.
116. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. J Urol 2003;170:S84.
117. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24.
118. Wittel UA, Jain M, Goel A, et al. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol 2005;32:157.
119. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823.
120. Rossi EA, Chang CH, Losman MJ, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res 2005;11:7122s.
121. Pagel JM, Lin Y, Hedin N, et al. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood 2006;108:328.
122. DeNardo SJ, Richman CM, Albrecht H, et al. Enhancement of the therapeutic index: From nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin Cancer Res 2005;11:7187s.
123. Dwyer RM, Bergert ER, O'Connor MK, et al. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005;11:1483.
124. Wittel UA, Jain M, Goel A, et al. Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49. Biochem Biophys Res Commun 2005;329:168.
125. Ebbinghaus C, Ronca R, Kaspar M, et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 2005;116:304.
126. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540.
127. Dijoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006;12:242.
128. Bang S, Nagata S, Onda M, et al. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11:1545.
129. Alderson RF, Toki BE, Roberge M, et al. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme pro-drug therapy (ADEPT). Bioconj Chem 2006;17:410.
130. Hay es ME, Drummond DC, Kirpotin DB, et al. Genospheres: Self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther 2005;1.
131. 111In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res 2005;11:7087s.
132. Aktas Y, Yemisci M, Andrieux K, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconj Chem 2005;16:1503.
133. Lobato MN, Rabbitts TH. Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med 2003;9:390.
134. Ewert S, Honegger A, Pluckthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 2004;34:184.
135. Revets H, De BP, Muyldermans S. Nanobodies as novel agents for cancer therapy. Exp Opin Biol Ther 2005;5:111.
136. Marini P, Denzinger S, Schiller D, et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006;in press.
137. Nahleh ZA, Jazieh AR. Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer. Am J Clin Oncol 2005;28:631.
138. Studer M, Meares CF. Synthesis of novel 1,4,7-triazacyclononane-N, N′,N″-triacetic acid derivatives suitable for protein labeling. Bioconj Chem 1992;3:337.
139. Gampel A, Moss L, Jones MC, et al. VEGF regulates the mobilisation of VEGFR-2/KDR from an intracellular endothelial storage compartment. Blood 2006;in press.